Skip to main content

Drug rejected by NICE on the NHS for people with multiple sclerosis

The National Institute for Health and Care Excellence (NICE) is not recommending Ponvory (ponesimod) is made available on the NHS in England and Wales for people with active, relapsing forms of multiple sclerosis (MS).

NICE’s decision currently applies to England and Wales, though Northern Ireland tends to follow the same guidance following a review. In Scotland, the Scottish Medicines Consortium will decide next month whether it will be available there on the NHS.

This is the second rejection of an oral drug for MS in just five months. NICE rejected Zeposia (ozanimod) in May for England and Wales, though it was approved for Scotland. NICE said it found neither treatment to be cost effective.

Anyone wishing to share their experience with the drug and how they think it would make a difference for those living with MS should email their opinions to campaigns@msslociety.org.uk 

Source: MS-UK 13 October 2021

Read next: New clues for predicting rare brain infection linked to MS drug Tysabri

Read next: Drug found to reduce bladder pressure in people with MS